1. A synthetic triacylated pseudo-dipeptide molecule promotes Th1/TReg immune responses and enhances tolerance induction via the sublingual route.
- Author
-
Mascarell L, Van Overtvelt L, Lombardi V, Razafindratsita A, Moussu H, Horiot S, Chabre H, Limal D, Moutel S, Bauer J, Chiavaroli C, and Moingeon P
- Subjects
- Administration, Sublingual, Animals, CD4-Positive T-Lymphocytes drug effects, CD4-Positive T-Lymphocytes physiology, Cell Polarity, Dendritic Cells drug effects, Dendritic Cells physiology, Female, Humans, Interferon-gamma biosynthesis, Mice, Mice, Inbred BALB C, Adjuvants, Immunologic pharmacology, Desensitization, Immunologic methods, Dipeptides pharmacology, Immune Tolerance, T-Lymphocytes, Regulatory immunology, Th1 Cells immunology
- Abstract
In this study, we tested two triacylated pseudo-dipeptidic molecules, OM-197-MP-AC and OM-294-BA-MP as candidate adjuvants for allergy vaccines. Both molecules induce human dendritic cell (h-DC) maturation and polarize naïve T cells toward the Th1 type with IFNgamma production. Only OM-294-BA-MP induces IL10 gene expression both in monocyte-derived DCs and CD4+ naïve T cells. Sublingual administration of OM-294-BA-MP plus the antigen enhances tolerance induction in BALB/c mice with established asthma to ovalbumin with an impact on both airways hyperresponsiveness and lung inflammation. Given its Th1/Treg polarizing properties, OM-294-BA-MP is a valid candidate for sublingual allergy vaccines.
- Published
- 2007
- Full Text
- View/download PDF